SAN FRANCISCO, Jan. 19 /CNW/ - In connection with meetings during the
J.P. Morgan Healthcare Conference in San Francisco, Patient Home
Monitoring (PHM) (TSXV:PHM), a company focused on in-home cardiology
healthcare services, today announced the release of an interview with
the Company's CEO Ed Berenblum. The interview covers a brief history on
PHM, the company's unique business model and Ed's move from Genpact
(NYSE: G) to take on the position of Chief Executive Officer.
Investors can find the 40-minute in-depth interview on the PHM investor
relations website: www.phmhometesting.com.
For additional information please refer to the Company's website and
complete filings at www.sedar.com.
PHM is a healthcare services company focused on providing in-home
testing for patients on blood thinner medications such as Coumadin or
warfarin. Medicare recently expanded reimbursement for in-home patient
self testing (PST) of blood coagulation levels. PHM has a unique value
proposition for cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This
unique, systemized approach creates an opportunity for physician groups
to operate more efficiently, increasing revenue to their clinic while
providing a higher standard of care for patients.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the future outlook of PHM and anticipated
events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it.
While these assumptions were considered reasonable by PHM at the time
of preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and uncertainties,
including the availability of funds and resources to pursue operations,
decline of reimbursement rates, dependence on few payors, possible new
drug discoveries, a novel business model, dependence on key suppliers,
granting of permits and licenses in a highly regulated business,
competition, low profit market segments as well as general economic,
market and business conditions, and could differ materially from what
is currently expected.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE PHM Patient Home Monitoring
For further information:
|Michael Dalsin |
Chairman, Patient Home Monitoring
Managing Director, Stanmore Capital Partners, Inc.